Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...